Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 2,100 shares, a drop of 86.6% from the February 28th total of 15,700 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 21.0 days. Currently, 0.0% of the company’s stock are short sold.

Basilea Pharmaceutica Stock Performance

OTCMKTS BPMUF remained flat at $54.00 on Friday. Basilea Pharmaceutica has a 12 month low of $38.60 and a 12 month high of $54.00. The company’s fifty day simple moving average is $52.92 and its 200-day simple moving average is $52.60. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.